SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World’s First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment

Introducing Visiopharm PhenomapTM Multiplexing a novel software tool to help you streamline and automate the analysis workflow of high dimensional multiplex datasets, for deeper understanding of potential relationships in the tumor...

Researchers studying microvascular networks and vessels have a groundbreaking new software application to facilitate their work. Developed by MBF Bioscience, Vesselucida® 360 automatically reconstructs and analyzes microvascular networks in...

Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue...

Stop by booth B1 at the Euskalduna Conference Centre for a hands-on experience using the next-generation of the popular Omnyx Dynamyx digital pathology software. Inspirata, Inc. - September 06, 2018 01:00 ET Bilbao, Spain, Sept. 06, 2018...

Webinar Weds., September 26, 2018 @ 2 p.m. EDT; 1 p.m. CDT; 12 p.m. MDT; 11 a.m. PDT Register Now! Attracting clients is easy—keeping them is hard work! With the high cost of new-client acquisitions, it’s crucial to...

A year ago tonight I received a phone call from my primary care physician, late on a Friday night, before a long 3-day holiday weekend. Can’t be good news I thought. The conversation went something like this: Dr. Feinberg: Dr. Kaplan, this...